Gene Therapy for Visual-System Disease: Functional Readouts for Preclinical Efficacy Assessment

However, molecular confirmation of transduction (immunohistochemistry, qPCR, ERG a-/b-wave amplitude) does not necessarily predict whether the treated animal recovers functional vision. ERG measures electrical responses across the retina but requires instrumentation and does not directly report on the optomotor reflex arc or cortical processing. Histological endpoints are terminal and cannot provide longitudinal data from the same animal. The optomotor reflex, measured by OptoDrum, captures the integrated output of whichever retinal pathway was rescued and reports it as a spatial acuity threshold – the most direct non-invasive proxy for vision.

Also see: Rare & Inherited CNS and Eye Disorders and Rare Disease.

Age-related visual decline and glaucomatous RGC loss share a common epigenetic underpinning: the progressive divergence of the retinal epigenome from its youthful state, impairing axon regeneration capacity and neuronal survival. Partial reprogramming using Yamanaka factors – specifically the OSK subset that excludes the oncogenic cMyc – can reset this epigenetic drift without inducing pluripotency. Delivered by AAV to RGCs, OSK has the potential to reverse both the age-associated loss of acuity and the RGC degeneration characteristic of glaucoma.

Demonstrating that this molecular reprogramming produces genuine functional vision recovery requires a longitudinal, non-terminal behavioural endpoint. Terminal readouts (RGC counts, axon density, ERG implicit time) confirm cellular rescue but cannot establish that the treated animal sees better. Histological endpoints from the same cohort eliminate the possibility of comparing before/after function in the same animal. OptoDrum measurements taken at baseline, during disease progression, and at multiple post-treatment timepoints provide exactly this longitudinal functional data without sacrificing the animal, enabling the researcher to track recovery trajectories and confirm that improvement is durable rather than transient.

Also see: Glaucoma & Optic Nerve Neurodegeneration, Systemic Aging & CNS Decline and RGC Pathology.

Most inherited retinal dystrophies (retinitis pigmentosa, Leber congenital amaurosis, choroideremia, CNGB1/CNGA1-associated RP) affect rod photoreceptors primarily, with cone involvement typically following rod loss. A gene therapy designed to rescue rod photoreceptors – for example, by restoring a rod-expressed protein (CNGB1, RPGR, RHO) – should ideally be evaluated with an endpoint that specifically isolates rod function. Electroretinography provides a- and b-wave amplitudes that partly dissect rod and cone contributions, but requires anaesthesia, electrode placement, and is not readily repeatable at daily resolution.

The OptoDrum under standard photopic conditions measures cone/mixed spatial acuity and contrast sensitivity. This endpoint captures cone-mediated vision but conflates rod recovery with overall acuity. The ScotopicKit extends optomotor testing to scotopic luminance levels (stepped down in 1 log-unit increments), at which only rod photoreceptors can drive the reflex arc at the low spatial frequencies tested. This scotopic OMR endpoint isolates rod rescue and is repeatable across longitudinal timepoints without anaesthesia. Together, the two instruments provide a rod/cone functional profile that mirrors the clinical distinction between night-vision and day-vision deficits.

Also see: Retinal Degeneration & Inherited Retinal Disease and Retinal Degeneration .

Gene therapy clinical development requires establishing a minimum effective dose (MED) and a maximum tolerated dose (MTD) to define the therapeutic window. For retinal gene therapy, the dose determines how many cells are transduced (coverage), which in turn determines whether sufficient signal is restored to cross the threshold for behavioural visual function. Below the coverage threshold, transduced cells may express the therapeutic transgene at the protein level, but the density of rescued cells is insufficient to drive an optomotor response above the noise floor.

Dose-response assessment with histological or biochemical endpoints (transgene copy number, immunohistochemistry of transduced cells) confirms that the vector reached the retina but does not report on the functional consequence. ERG provides an electrophysiological dose-response but requires anaesthesia and head-immobilisation. OptoDrum closes this gap by providing a non-invasive, repeatable functional readout across the full AAV dose range in the same animal cohort, allowing the functional dose-response curve to be constructed without terminal sampling at each dose level.

Note that AAV dose-response for optogenetic payloads (ChR variants, Jaws, SOUL) follows the same principle, but the functional threshold for optogenetic restoration differs from classical gene supplementation because the optogenetic actuator must achieve sufficient expression density in the target cells (typically surviving inner retinal neurons) to generate a light-driven retinal output signal above the noise floor of the remaining circuitry.

Also see: Blindness

In gene therapy efficacy studies, the primary endpoint of clinical relevance is always functional: does the patient see better? In preclinical rodent studies, this translational alignment is frequently lost because histological endpoints are technically straightforward, highly sensitive, and unambiguous for publication, whereas functional behavioural testing adds time, equipment, and operator expertise to the protocol. The result is that many published gene therapy studies demonstrate excellent photoreceptor or RGC preservation histologically without confirming that the preserved cells actually produce functional visual signal.

This gap is significant for translation because histological preservation does not guarantee functional rescue: cells may survive but lose their electrophysiological properties (e.g., opsin misfolding, synaptic rewiring, or inner retinal remodelling in late-stage degeneration). Conversely, small numbers of transduced cells that are functionally intact may restore sufficient signal to cross the behavioural threshold even when structural counts appear modest. Only a functional endpoint – the optomotor reflex or operant acuity – resolves this ambiguity.

Also see: Maintaining & Restoring Vision.